The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | Correlation between extreme BMI and survival in patients with multiple myeloma
Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses findings from a study evaluating the correlation between extreme body mass index (BMI) and survival in patients with newly diagnosed multiple myeloma (NDMM). Dr Shah explains that patients with either upper or lower extreme BMI were more likely to have a slight decrease in progression-free survival (PFS) or overall survival (OS) compared to patients with normal BMI, and identifies possible explanations for this trend. To conclude, Dr Shah emphasizes the importance of understanding the role of weight in outcomes for patients with plasma cell disorders. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Janssen, BMS and Sanofi
Honoraria: MJH Life Sciences, Janssen, ACCC, MashUpMD, RedMedEd
